• Journal Article

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification

Citation

Morishima, C., Chung, M., Ng, K. W., Brambilla, D., & Gretch, D. R. (2004). Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. Journal of Clinical Microbiology, 42(1), 421-425.

Abstract

The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantified specimens by 2.5- to 10.6-fold even at relatively low hepatitis C virus RNA concentrations. Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay